Group 1 - AGF Investments Inc. announced cash distributions for February 2026 for three funds: AGF Enhanced U.S. Equity Income Fund, AGF Total Return Bond Fund, and AGF Systematic Global Infrastructure ETF, with payments scheduled for March 5, 2026 [1] - The cash distribution amounts per unit are as follows: AGF Enhanced U.S. Equity Income Fund at $0.181211, AGF Total Return Bond Fund at $0.092000, and AGF Systematic Global Infrastructure ETF at $0.160670 [1] Group 2 - AGF Management Limited, founded in 1957, is an independent asset management firm with over $59 billion in total assets under management, serving more than 820,000 investors [7] - AGF operates through three business lines: AGF Investments, AGF Capital Partners, and AGF Private Wealth, focusing on responsible and sustainable corporate practices [5][6] - AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, managing mutual funds in Canada [8][9]

Core Insights - Kane Biotech Inc. has published an article on its revyve Antimicrobial wound gel in the International Wound Journal, highlighting the gel's wound healing properties and antimicrobial activity [1][2] Group 1: Publication and Validation - The article titled "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity" is authored by Dr. Jeyachchandran Visvalingam and includes contributions from the University of Miami [1] - The publication in a peer-reviewed journal underscores the scientific rigor of revyve technology and provides independent validation of the gel's safety and clinical potential [3] Group 2: Product Efficacy and Features - The revyve Antimicrobial Wound Gel demonstrates efficacy against a range of wound-related pathogens, achieving a 99.99% to 99.9999% reduction in bacterial counts within 30 minutes [7] - The gel exhibits sustained in vitro activity for up to 7 days, potentially reducing the frequency of dressing changes [7] - It is designed as a thermo-reversible gel that transitions from a liquid to a gel at body temperature, allowing for easy removal [7] Group 3: Company Overview - Kane Biotech is focused on developing novel wound care treatments that target biofilms, which contribute to antibiotic resistance and adverse clinical outcomes [4] - The revyve product line, including the Antimicrobial Wound Gel and Spray, has received U.S. FDA 510(k) clearance and Health Canada approval [4]

Group 1 - BHP Group Limited and Faraday Copper Corp. have signed a non-binding letter of intent to explore a potential acquisition of BHP's San Manuel property by Faraday, with BHP receiving a 30% equity interest in Faraday in return [1][2] - The LOI aims to facilitate the restart of the San Manuel copper mine and the development of a new copper hub in Arizona, leveraging existing infrastructure and enhancing capital efficiency [2] - The San Manuel mine was a significant copper producer in the US until its closure in 1999 due to low copper prices, leaving a substantial mineral inventory [3] Group 2 - BHP is the world's largest copper producer, with operations in over 90 countries, focusing on safety, operational excellence, and long-term value creation [4]

Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]

Core Viewpoint - Aquestive Therapeutics announced the investigational use of Anaphylm™ (dibutepinephrine) sublingual film, which achieved clinically relevant epinephrine plasma concentrations without causing a dip in diastolic blood pressure, highlighting its potential to transform anaphylaxis management [1][2]. Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact, requiring no water or swallowing for administration [3]. - The product's packaging is designed to be portable and weather-resistant, making it easy to carry in a wallet or phone [3]. - If approved by the FDA, Anaphylm would be the first oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis [3]. Group 2: Clinical Data and Presentations - Multiple poster presentations at the 2026 AAAAI Annual Meeting will showcase the clinical data for Anaphylm, emphasizing its differentiated profile and potential for meaningful outcomes [2]. - Key findings include the absence of a diastolic blood pressure dip following sublingual administration, which is a significant clinical concern in anaphylaxis treatment [2]. Group 3: Company Overview - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, operating as both a product developer and a Contract Development and Manufacturing Organization (CDMO) [5]. - The company has a portfolio that includes four commercialized products and a library of over 20 epinephrine prodrugs for various allergy and dermatological indications [5].

Group 1 - VitalHub Corp. will release its financial results for Q4 2025 on March 12, 2026, after market close [1] - A conference call will be held on March 13, 2026, at 9:00 am EST, hosted by CEO Dan Matlow and CFO Brian Goffenberg [1] - The company serves over 1,000 clients globally, focusing on health and human services [2] Group 2 - VitalHub has a two-pronged growth strategy that includes organic growth within its product suite and an aggressive M&A plan [2] - The company is headquartered in Toronto and has over 500 employees worldwide, including a VitalHub Innovations Lab in Sri Lanka [2]

Core Viewpoint - EVgo Inc. is set to release its fourth quarter and full year 2025 financial results on March 3, 2026, followed by a management-hosted webcast [1]. Group 1: Financial Results Announcement - The financial results will be released on Tuesday, March 3, 2026, at 8 a.m. ET (5 a.m. PT) [2]. - A press release with the financial results and a presentation will be available on EVgo's Investor Relations website prior to the webcast [2]. Group 2: Company Overview - EVgo is one of the largest public fast charging providers in the U.S., operating over 1,200 fast charging stations across 47 states [3]. - The company partners with various businesses, including retailers, grocery stores, and rideshare operators, to enhance the accessibility of its charging infrastructure [3]. - EVgo conducts interoperability testing at its Innovation Lab and collaborates with leading automakers to improve the EV charging experience [3].

SINGAPORE, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (Nasdaq: BTDR) (“Bitdeer”), a world-leading technology company for Bitcoin mining and AI infrastructure, today announced the pricing of its registered direct offering of 5,503,030 of its Class A ordinary shares, par value US$0.0000001 per share (the “Class A ordinary shares”), to certain holders of its 5.25% convertible senior notes due 2029 (the “November 2029 notes”) at a price of US$7.94 per Class A ordinary share in a direct placeme ...

Five-year syndicated credit facility at an industry-leading rate of SOFR+500CHICAGO and VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced the Company increased its existing syndicated credit facility led by Valley National Bank by $50 million, bringing the total facility to $189 million. The Company i ...

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) is pleased to announce high-grade gold results from a 2025 rock sampling program, resulting in the establishment of a new land position at the Carter Gulch Property (or “the Property”), located 40 kilometres southwest of Whitehorse, Yukon and 10 kilometres from the Alaska Highway. Highlights: High-grade gold identified from 2025 rock sampling, including up t ...